Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Practice Patterns in the Treatment of Patients With Severe Alcohol Withdrawal: A Multidisciplinary, Cross-Sectional Survey.

Buell D, Filewod N, Ailon J, Burns KEA.

J Intensive Care Med. 2019 May 23:885066619847119. doi: 10.1177/0885066619847119. [Epub ahead of print]

PMID:
31122170
2.

Integration of genomic and clinical data augments surveillance of healthcare-acquired infections.

Ward DV, Hoss AG, Kolde R, van Aggelen HC, Loving J, Smith SA, Mack DA, Kathirvel R, Halperin JA, Buell DJ, Wong BE, Ashworth JL, Fortunato-Habib MM, Xu L, Barton BA, Lazar P, Carmona JJ, Mathew J, Salgo IS, Gross BD, Ellison RT.

Infect Control Hosp Epidemiol. 2019 Jun;40(6):649-655. doi: 10.1017/ice.2019.75. Epub 2019 Apr 23.

PMID:
31012399
3.

PTSD psychotherapy improves blood pressure but leaves HPA axis feedback sensitivity stable and unaffected: First evidence from a pre-post treatment study.

Schubert CF, Schreckenbach M, Kirmeier T, Gall-Kleebach DJ, Wollweber B, Buell DR, Uhr M, Rosner R, Schmidt U.

Psychoneuroendocrinology. 2019 Feb;100:254-263. doi: 10.1016/j.psyneuen.2018.10.013. Epub 2018 Oct 22.

PMID:
30391833
4.

The efficacy and safety of pre-hospital cooling after out-of-hospital cardiac arrest: a systematic review and meta-analysis.

Lindsay PJ, Buell D, Scales DC.

Crit Care. 2018 Mar 13;22(1):66. doi: 10.1186/s13054-018-1984-2. Review.

5.

Proportion of women presenters at medical grand rounds at major academic centres in Canada: a retrospective observational study.

Buell D, Hemmelgarn BR, Straus SE.

BMJ Open. 2018 Jan 18;8(1):e019796. doi: 10.1136/bmjopen-2017-019796.

6.

In Vitro Fertilization Success Rates after Surgically Treated Endometriosis and Effect of Time Interval between Surgery and In Vitro Fertilization.

AlKudmani B, Gat I, Buell D, Salman J, Zohni K, Librach C, Sharma P.

J Minim Invasive Gynecol. 2018 Jan;25(1):99-104. doi: 10.1016/j.jmig.2017.08.641. Epub 2017 Aug 12.

PMID:
28807807
7.

Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Seibel NL, Shad AT, Bekersky I, Groll AH, Gonzalez C, Wood LV, Jarosinski P, Buell D, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01477-16. doi: 10.1128/AAC.01477-16. Print 2017 Feb.

8.

miRNAs and other non-coding RNAs in posttraumatic stress disorder: A systematic review of clinical and animal studies.

Schmidt U, Keck ME, Buell DR.

J Psychiatr Res. 2015 Jun;65:1-8. doi: 10.1016/j.jpsychires.2015.03.014. Epub 2015 Mar 24. Review.

PMID:
25896120
9.

Identification and characterization of HPA-axis reactivity endophenotypes in a cohort of female PTSD patients.

Zaba M, Kirmeier T, Ionescu IA, Wollweber B, Buell DR, Gall-Kleebach DJ, Schubert CF, Novak B, Huber C, Köhler K, Holsboer F, Pütz B, Müller-Myhsok B, Höhne N, Uhr M, Ising M, Herrmann L, Schmidt U.

Psychoneuroendocrinology. 2015 May;55:102-15. doi: 10.1016/j.psyneuen.2015.02.005. Epub 2015 Feb 16.

PMID:
25745955
10.

A role for synapsin in FKBP51 modulation of stress responsiveness: Convergent evidence from animal and human studies.

Schmidt U, Buell DR, Ionescu IA, Gassen NC, Holsboer F, Cox MB, Novak B, Huber C, Hartmann J, Schmidt MV, Touma C, Rein T, Herrmann L.

Psychoneuroendocrinology. 2015 Feb;52:43-58. doi: 10.1016/j.psyneuen.2014.11.005. Epub 2014 Nov 11.

PMID:
25459892
11.

Therapeutic Action of Fluoxetine is Associated with a Reduction in Prefrontal Cortical miR-1971 Expression Levels in a Mouse Model of Posttraumatic Stress Disorder.

Schmidt U, Herrmann L, Hagl K, Novak B, Huber C, Holsboer F, Wotjak CT, Buell DR.

Front Psychiatry. 2013 Jul 10;4:66. doi: 10.3389/fpsyt.2013.00066. eCollection 2013.

12.

Leveraging data and analytics to generate new revenue.

Buell D.

Healthc Financ Manage. 2013 Apr;67(4):40-2, 44.

PMID:
23596830
13.

Segmenting patient accounts: a balance between compassion and collections.

Buell D.

Revenue-cycle Strateg. 2012 Sep;9(7):4-6. No abstract available.

PMID:
23025216
14.

Long-lasting hippocampal synaptic protein loss in a mouse model of posttraumatic stress disorder.

Herrmann L, Ionescu IA, Henes K, Golub Y, Wang NX, Buell DR, Holsboer F, Wotjak CT, Schmidt U.

PLoS One. 2012;7(8):e42603. doi: 10.1371/journal.pone.0042603. Epub 2012 Aug 10.

15.

Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons.

Ionescu IA, Dine J, Yen YC, Buell DR, Herrmann L, Holsboer F, Eder M, Landgraf R, Schmidt U.

Neuropsychopharmacology. 2012 May;37(6):1323-37. doi: 10.1038/npp.2011.317. Epub 2012 Jan 25.

16.

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.

Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, Buell DN, Kovanda LL, Bhavnani SM.

Antimicrob Agents Chemother. 2011 May;55(5):2113-21. doi: 10.1128/AAC.01430-10. Epub 2011 Feb 7.

17.

Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials.

Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN, Kovanda L, Lortholary O.

Clin Infect Dis. 2010 Aug 1;51(3):295-303. doi: 10.1086/653935.

PMID:
20578829
18.

Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5'-untranslated region.

Lammich S, Buell D, Zilow S, Ludwig AK, Nuscher B, Lichtenthaler SF, Prinzen C, Fahrenholz F, Haass C.

J Biol Chem. 2010 May 21;285(21):15753-60. doi: 10.1074/jbc.M110.110742. Epub 2010 Mar 26.

19.

Population pharmacokinetics of micafungin in neonates and young infants.

Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A, Walsh TJ, Cohen-Wolkowiez M, Benjamin DK Jr.

Antimicrob Agents Chemother. 2010 Jun;54(6):2633-7. doi: 10.1128/AAC.01679-09. Epub 2010 Mar 22.

20.

Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.

Horn DL, Ostrosky-Zeichner L, Morris MI, Ullmann AJ, Wu C, Buell DN, Kovanda LL, Cornely OA.

Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):223-9. doi: 10.1007/s10096-009-0843-0. Epub 2009 Dec 15.

PMID:
20013016
21.

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

Benjamin DK Jr, Smith PB, Arrieta A, Castro L, Sánchez PJ, Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN, Hope WW, Walsh TJ.

Clin Pharmacol Ther. 2010 Jan;87(1):93-9. doi: 10.1038/clpt.2009.200. Epub 2009 Nov 4.

22.

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

Smith PB, Walsh TJ, Hope W, Arrieta A, Takada A, Kovanda LL, Kearns GL, Kaufman D, Sawamoto T, Buell DN, Benjamin DK Jr.

Pediatr Infect Dis J. 2009 May;28(5):412-5. doi: 10.1097/INF.0b013e3181910e2d.

23.

Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis.

Kontoyiannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdière M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA.

Transpl Infect Dis. 2009 Feb;11(1):89-93. doi: 10.1111/j.1399-3062.2008.00349.x. Epub 2008 Oct 8.

PMID:
18983417
24.

The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, Cotton MP, Bacher J, Keirns JJ, Buell D, Heresi G, Benjamin DK Jr, Groll AH, Drusano GL, Walsh TJ.

J Infect Dis. 2008 Jan 1;197(1):163-71. doi: 10.1086/524063.

25.

Population pharmacokinetics of micafungin in adult patients.

Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL.

Diagn Microbiol Infect Dis. 2008 Mar;60(3):329-31. Epub 2007 Nov 19.

PMID:
18024052
26.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN.

Clin Infect Dis. 2007 Oct 1;45(7):883-93. Epub 2007 Aug 29. Erratum in: Clin Infect Dis. 2008 Jul 15;47(2):302.

PMID:
17806055
27.

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.

Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ.

Antimicrob Agents Chemother. 2007 Oct;51(10):3714-9. Epub 2007 Jul 16.

28.

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.

Heresi GP, Gerstmann DR, Reed MD, van den Anker JN, Blumer JL, Kovanda L, Keirns JJ, Buell DN, Kearns GL.

Pediatr Infect Dis J. 2006 Dec;25(12):1110-5.

PMID:
17133155
29.

Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.

Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A.

Antimicrob Agents Chemother. 2007 Feb;51(2):787-90. Epub 2006 Nov 20.

30.

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF.

J Infect. 2006 Nov;53(5):337-49. Epub 2006 May 6.

PMID:
16678903
31.

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN.

Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):654-61. Erratum in: Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):69.

PMID:
16261306
32.

Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.

Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I.

J Clin Pharmacol. 2005 Oct;45(10):1145-52.

PMID:
16172179
33.

Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers.

Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, Bekersky I.

J Clin Pharmacol. 2005 Sep;45(9):1018-24.

PMID:
16100295
34.

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.

Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ.

Antimicrob Agents Chemother. 2005 Aug;49(8):3317-24.

35.

Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers.

Hebert MF, Townsend RW, Austin S, Balan G, Blough DK, Buell D, Keirns J, Bekersky I.

J Clin Pharmacol. 2005 Aug;45(8):954-60.

PMID:
16027407
36.

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.

de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E, Llanos EA, Fisco C, Lau W, Buell D.

Aliment Pharmacol Ther. 2005 Apr 1;21(7):899-907.

38.

Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.

Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D; FK463 South African Study Group.

Aliment Pharmacol Ther. 2004 Aug 15;20(4):475-81.

39.

Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics.

Roden MM, Nelson LD, Knudsen TA, Jarosinski PF, Starling JM, Shiflett SE, Calis K, DeChristoforo R, Donowitz GR, Buell D, Walsh TJ.

Clin Infect Dis. 2003 May 15;36(10):1213-20. Epub 2003 May 8.

PMID:
12746764
41.

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ.

Antimicrob Agents Chemother. 2002 Mar;46(3):828-33.

42.

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ.

Antimicrob Agents Chemother. 2001 Dec;45(12):3487-96.

43.

Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers.

Bekersky I, Fielding RM, Dressler DE, Kline S, Buell DN, Walsh TJ.

J Clin Pharmacol. 2001 Sep;41(9):963-71.

PMID:
11549101
44.

Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats.

Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ.

Pharm Res. 2000 Dec;17(12):1494-502.

PMID:
11303959
45.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V.

Blood. 2000 Sep 15;96(6):2062-8.

46.

Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs.

Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ.

Pharm Res. 1999 Nov;16(11):1694-701.

PMID:
10571274
47.

Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine.

Horowitz MM, Przepiorka D, Bartels P, Buell DN, Zhang MJ, Fitzsimmons WE, Erdman J, Huang C, Hodosh E, Maher R, Wingard JR.

Biol Blood Marrow Transplant. 1999;5(3):180-6.

48.

Lipid-based amphotericin B formulations: from animals to man.

Bekersky I I, Fielding RM, Buell D, Lawrence I I.

Pharm Sci Technolo Today. 1999 Jun;2(6):230-236.

PMID:
10366838
49.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.

Blood. 1998 Oct 1;92(7):2303-14.

50.

Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.

Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W.

Antimicrob Agents Chemother. 1998 Sep;42(9):2391-8.

Supplemental Content

Support Center